Hysbysiad contract
Adran I:
Awdurdod
contractio
I.1) Enw a chyfeiriad
Cell and Gene Therapy Catapult
12th Floor, Guy's Tower, Great Maze Pond
London
SE1 9RT
UK
E-bost: MCProcurement@ct.catapult.org.uk
NUTS: UKI1
Cyfeiriad(au) rhyngrwyd
Prif gyfeiriad: https://ct.catapult.org.uk/
I.3) Cyfathrebu
Mae mynediad at y dogfennau caffael yn gyfyngedig. Gellir cael rhagor o wybodaeth yn:
https://ct.catapult.org.uk
Gellir cael gwybodaeth ychwanegol o'r cyfeiriad uchod
Rhaid anfon tendrau neu geisiadau i gymryd rhan i'r cyfeiriad uchod:
I.4) Y math o awdurdod contractio
Arall: Partially funded through another contracting authority
I.5) Prif weithgaredd
Arall: Cell and gene therapies
Adran II: Gwrthrych
II.1) Cwmpas y caffaeliad
II.1.1) Teitl
The Supply and Implementation of a Laboratory Information Management System.
Cyfeirnod: CON-0082
II.1.2) Prif god CPV
48000000
II.1.3) Y math o gontract
Gwasanaethau
II.1.4) Disgrifiad byr
This procurement is for the supply, implementation and support of a Laboratory Information Management System (LIMS) for Cell and Gene Therapy Catapult (CGTC). The LIMS solution will cover two sites, primarily the CGTC Manufacturing Centre in Stevenage with a subset of system functionality available for use at CGTC's Guys Hospital location. CGTC is committed to implementing an LIMS system as a priority in time for the opening of the Manufacturing Centre in July 2017. Completion of formal GMP system qualification would be required to be completed no later than November 2017 in anticipation of inspection for licensure in December 2017.
II.1.5) Cyfanswm gwerth amcangyfrifedig
Gwerth heb gynnwys TAW: 300 000.00 GBP
II.1.6) Gwybodaeth am lotiau
Mae’r contract hwn wedi’i rannu’n lotiau:
Na
II.2) Disgrifiad
II.2.3) Man cyflawni
Cod NUTS:
UKH23
Prif safle neu fan cyflawni:
Stevenage.
II.2.4) Disgrifiad o’r caffaeliad
Cell and Gene Therapy Catapult (CGTC) is part of a world-leading network of technology and innovation centres. Established in December 2012 and now with over 100 employees, we believe through science and industry, our expertise in cell and gene therapies will one day provide better treatments that will help improve patient quality of life whilst building a global industry the UK can be proud of. Our mission to deliver health and wealth is supported by the UK's enviable academic base. We strive to be a world leader in cell and gene therapy and support those who wish to convert research into products that have the potential to have direct impact in advanced healthcare.
CGTC is not alone in this ambition. Regenerative medicine is 1 of the government's 8 great technologies that support UK science strengths and capabilities.
CGTC's offices are located in Guys Hospital in London. CGTC are building a 55 000 000 GBP large-scale GMP Manufacturing Centre to help bring cell and gene therapies to market in the UK and internationally. It will provide the UK with the manufacturing facilities needed for later-stage cell and gene therapy clinical studies and commercialisation. The centre benefits from an established supply chain, prime UK location in Stevenage and expert impartial advice from the Cell and Gene Therapy Catapult, enabling the manufacture of therapies to the highest grade, with minimal risk and 100 percent control.
This procurement is for the supply, implementation and support of a Laboratory Information Management System (LIMS) for CGTC. The LIMS solution will cover two sites, primarily the manufacturing centre in Stevenage with a subset of system functionality available for use at CGTC's Guys Hospital location.
The new LIMS will negate the need for numerous ad hoc laboratory data management systems as currently used at the Guys hospital site and will bring a fully integrated and validated LIMS solution to the Stevenage Manufacturing Centre.
The budget for the requirement is between 200 000 GBP and 300 000 GBP over 5 years (3 years initially plus two potential further periods of up to 24 months).
II.2.5) Meini prawf dyfarnu
Nid pris yw’r unig faen prawf dyfarnu a dim ond yn y dogfennau caffael y mae’r holl feini prawf wedi’u nodi
II.2.6) Gwerth amcangyfrifedig
Gwerth heb gynnwys TAW: 300 000.00 GBP
II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig
Hyd mewn misoedd: 60
Gall y contract hwn gael ei adnewyddu: Na
II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd
II.2.10) Gwybodaeth am amrywiadau
Derbynnir amrywiadau:
Na
II.2.11) Gwybodaeth am opsiynau
Opsiynau:
Na
II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd
Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd:
Na
II.2.14) Gwybodaeth ychwanegol
To express an interest to received the tender documents you must provide your contact name, position in company, company name, address, email and direct phone contact details to MCProcurement@ct.catapult.org.uk
Section III: Gwybodaeth gyfreithiol, economaidd, ariannol a thechnegol
III.1) Amodau ar gyfer cymryd rhan
III.1.2) Statws economaidd ac ariannol
Meini prawf dethol fel y’u nodir yn y dogfennau caffael
III.1.3) Gallu technegol a phroffesiynol
Meini prawf dethol fel y’u nodir yn y dogfennau caffael
III.2) Amodau sy’n gysylltiedig â’r contract
Section IV: Gweithdrefn
IV.1) Disgrifiad
IV.1.1) Y math o weithdrefn
Gweithdrefn agored
IV.1.8) Gwybodaeth am Gytundeb Caffael y Llywodraeth (GPA)
The procurement is covered by the Government Procurement Agreement:
Ydy
IV.2) Gwybodaeth weinyddol
IV.2.1) Cyhoeddiad blaenorol mewn perthynas â’r weithdrefn hon
Rhif yr hysbysiad yn OJ S:
2016/S 112-198760
IV.2.2) Terfyn amser i dendrau neu geisiadau i gymryd rhan ddod i law
Dyddiad:
27/01/2017
Amser lleol: 17:00
IV.2.4) Ym mha iaith/ieithoedd y gellir cyflwyno tendrau neu geisiadau i gymryd rhan
EN
IV.2.6) Yr isafswm cyfnod gofynnol i’r sawl sy’n tendro gynnal y tendr
Hyd mewn misoedd: 3 (o’r dyddiad a nodwyd i dendr ddod i law)
IV.2.7) Amodau ar gyfer agor tendrau
Dyddiad:
27/01/2017
Amser lleol: 17:00
Section VI: Gwybodaeth ategol
VI.1) Gwybodaeth am ailddigwydd
Caffaeliad cylchol yw hwn:
Na
VI.4) Gweithdrefnau adolygu
VI.4.1) Corff adolygu
Cell and Gene Therapy Catapult
London
SE1 9RT
UK
VI.5) Dyddiad anfon yr hysbysiad hwn
11/12/2016